breast cancer
Conditions
Interventions
Dual-target group (exposure group): neoadjuvant therapy with chemotherapy plus Trastuzumab and Pertuzumab or Pyrotinib:None
Single target group (non exposure group): chemotherapy+Trastuzumab:None
Sponsors
Guangxi Medical University Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.According to the ACJJ breast cancer stage, the TNM stage at the first diagnosis is IIA, IIB, IIIA, IIIB, IIIC, breast cancer patients who are to undergo surgery and new adjuvant treatment in accordance with NCCN guidelines can also be included in the study if the patient's axillary lymph nodes are negative and the tumor size >= 2cm; 2.The patient was pathologically diagnosed as invasive breast cancer, and HER-2 expression was positive in breast cancer. HER-2 expression was defined as an immunohistochemical score of 3+or HER2 amplification rate of FISH >= 2; 3.Female patients aged 18-70 years; 4.General situation: ECOG 0-2; 5.The patient underwent imaging examinations (including mammography, CT and/or PET/CT, breast ultrasound and/or breast MRI) before, during, and after neoadjuvant therapy, and was assessed as unsuitable for stage I breast conserving surgery before surgery; 6.The patient's neoadjuvant therapy regimen includes anti-HER-2 targeted drugs;
Exclusion criteria
Exclusion criteria: 1.Inflammatory breast cancer; 2.Metastatic breast cancer; 3.Previous ipsilateral breast cancer history; 4.Previous breast radiotherapy or systemic treatment for breast cancer; 5.Pregnant or lactating women; 6.Patient experiences disease progression during neoadjuvant therapy; 7.The patient has other malignant tumors besides breast cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Breast conserving surgery rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological complete remission rate;Incidence of drug-related adverse reactions;Overall survival rate;Disease-Free Survival;Local recurrence rate; | — |
Countries
China
Contacts
Public ContactYang Huawei
Guangxi Medical University Cancer Hospital
Outcome results
None listed